Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13222684 | 0.91 | FFAR1 (0.44) | POLBNR1H4HPGDFFAR1 | |
| SCHEMBL3053045 | 0.91 | FFAR1 (0.44) | POLBNR1H4HPGDFFAR1 | |
| SCHEMBL13222719 | 0.85 | FFAR1 (0.36) | SMN1; SMN2POLBKDM4ETSHRALDH1A1 | |
| SCHEMBL13243700 | 0.85 | NR1H4 (0.36) | SMN1; SMN2POLBKDM4ENR1H4KMT2A | |
| SCHEMBL13243314 | 0.85 | NR1H4 (0.36) | SMN1; SMN2POLBKDM4ENR1H4KMT2A | |
| SCHEMBL29423934 | 0.81 | FFAR1 (0.35) | SMN1; SMN2POLBKDM4ETSHRALDH1A1 | |
| SCHEMBL16846001 | 0.81 | FFAR1 (0.35) | SMN1; SMN2POLBKDM4ETSHRALDH1A1 | |
| SCHEMBL9903732 | 0.78 | NR1H4 (0.38) | POLBNR1H4HPGDFFAR1 | |
| SCHEMBL29423905 | 0.77 | FFAR1 (0.42) | POLBKMT2AMEN1FFAR1 | |
| SCHEMBL29423928 | 0.77 | FFAR1 (0.42) | POLBKMT2AMEN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399507-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2215068-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2215068-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2009058237-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | SMN1; SMN2 4810/4885POLB 4681/4885KDM4E 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.